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Abstract
Background: Kudiezi (KDZ) injection is commonly used in traditional Chinese medicine as treatment for cerebral
infarction and angina pectoris. The present study investigated the therapeutic effects of KDZ injection on myocardial
injury induced by acute cerebral ischemia and the possibly protective mechanisms.
Methods: Rats were divided into three groups: sham, 6h-ischemia, and KDZ treatment (KDZ). The neurological deficits
were determined by the Garcia score. The cerebral infarct volume was measured by 2,3,5-triphenyltetrazolium chloride
(TTC) staining, and brain water content was also evaluated. Serum creatinine kinase (CK), lactate dehydrogenase (LDH),
and creatine kinase-myocardial band (CK-MB) activity, myocardial tissue malondialdehyde (MDA) levels, L-Glutathione
(GSH) levels, and superoxide dismutase (SOD) activity as well as mitochondrial cytochrome c oxidase (COX) activity
were determined. Mitochondrial COX I and COX III mRNA expressions of myocardial tissues were measured by RT-PCR.
Results: Impaired neurological function and brain edema were observed in the 6h-ischemia group. TTC staining
showed that the 6h-ischemia group had larger infarct zones than the sham group. Myocardial ischemic changes
(widened myocardial cell gap, cracks, and obvious edema) were detected in the 6h-ischemia group compared with the
sham group, with elevated serum CK-MB activity and CK and LDH levels. Electrocardiography showed lower medium
frequency (MF) and high frequency (HF) in the 6h-ischemia group compared with the sham group. In myocardial
tissue, COX activity was elevated in the 6h-ischemia compared with the sham group, while SOD, GSH, and MDA levels,
and COX I and COX III mRNA expressions remained unchanged. KDZ injection decreased neurological impairment,
brain edema, gaps between cells, and infarct size. Compared with the 6h-ischemia group, it reduced serum CK-MB
activity and CK and LDH levels, and MDA levels in myocardial tissue. KDZ significantly increased GSH levels, SOD
activity, and mitochondria COX activity and the expression of COX I and COX III mRNA in myocardial tissue compared
with the sham group.
Conclusion: KDZ injection had a protective effect against cerebral ischemia in rats. KDZ injection could also alleviate
myocardial injury after acute cerebral ischemia in rats. The possible mechanisms involve the regulation of the oxidative
stress/antioxidant capacity after cerebral ischemia.
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Background
The most common cause of brain damage is hypoxia-
ischemia [1]. Focal brain ischemia or stroke is a leading
cause of death and adult disability. Although improving
the neurological symptoms is the primary goal of stroke
intervention, myocardial injury can occur during the
acute phase and the recovery period after a stroke.
Stroke-associated cardiac complications such as heart at-
tack, congestive heart failure, abnormal heart rhythms,
and cardiac arrest, may also lead to death [2, 3]. Of note,
2–6% of deaths are of cardiac origins in the first
3 months following ischemic stroke [3, 4]. It is also an
indication of an unfavorable prognosis in future stages
[5, 6]. Current clinical trials and animal experiments
studying myocardial injury induced by cerebrovascular
diseases mainly focused on cerebral hemorrhage and
subarachnoid hemorrhage and rarely on cerebral ische-
mia. A rodent model is needed to investigate the myo-
cardial injuries secondary to cerebrovascular diseases
and underlying mechanisms.
Oxidative stress plays an important role in the patho-
genesis of ischemic stroke. The formation of reactive
oxygen species (ROS) and free radicals induce damage
[7]. Oxidative stress is an imbalance between the pro-
duction of ROS and antioxidant factors of cells [8].
Oxidative stress has been shown to increase the levels of
lipid peroxidation, which may have a role in myocardial
tissue damage associated with acute cerebral ischemia
[9]. Cytochrome c oxidase (COX) is the key enzyme in
mitochondrial oxidative metabolism and is the terminal
electron transport oxidase in the mitochondrial respira-
tory chain. The association of oxidative stress and mito-
chondria was demonstrated by the up-regulation of
several COX genes involved in cellular oxidative stress
[10]. COX is a crucial component of the mitochondrial
respiratory chain and is of outmost importance for pro-
viding cellular energy [11]. Increased COX activity has
been associated with increased oxidative stress [10, 12],
but COX inhibition was also found to increase the sus-
ceptibility to oxidative stress and to accelerate mito-
chondrial apoptosis in response to oxidative stress [13].
Kudiezi (KDZ) injection extracted from the Chinese
herb Ixeris denticulateis one of many agents used in
traditional Chinese medicine for the treatment of ische-
mic stroke and myocardial infarction. It is approved by
the Chinese National Drug Administration. A study
showed that KDZ injection significantly reduced the de-
gree of neurological impairment (National Institutes of
Health Stroke Score (NIHSS)) and improved activities of
daily living (ADL) score in 166 patients with ischemic
stroke [14]. Zhou et al. [15] showed in 180 patients with
acute cerebral infarction that KDZ injection can reduce
serum highly-sensitive C-reactive protein (hs-CRP) and
interleukin (IL)-18 of patients with acute cerebral
infarction. Liu et al. [16] showed that KDZ injection can
reduce serum IL-6 and tumor necrosis factor (TNF)-α of
patients with acute cerebral infarction. These previous
studies also suggest that KDZ injection can improve pa-
tient quality of life. Pharmacological studies have shown
that KDZ injection can reduce IL-1β, TNF-α, and other
inflammatory cytokine expression, down-regulate the
protein expression of TLR4 and NOX4 (inflammatory
signaling pathways), improve the status of the middle
cerebral artery occlusion (MCAO) rat model of patho-
logical infarction, reduce cerebral infarct size, can regu-
late inflammatory responses, and has neuroprotective
effects in cerebral ischemia in rats [17, 18]. In vitro ex-
periments using human brain microvascular endothelial
cells showed that KDZ injection can downregulate the
expression of intercellular adhesion molecule (ICAM)-1
and vascular cell adhesion molecule (VCAM)-1 induced
by high glucose injury [19].
Nevertheless, the effects and mechanisms of KDZ in-
jection on myocardial injury after cerebral ischemia are
still unclear. In the present study, a rat model of acute
cerebral ischemia was established by MCAO. The thera-
peutic effect of KDZ injection on both brain and heart
were investigated, as well as the protective mechanisms.
Methods
KDZ injection
KDZ injection was obtained from TonghuaHuaxia
Pharmaceutical Co. Ltd. (Jilin, China; certification num-
ber: Z20025450). The ten active components of the KDZ
injection are shown in Fig. 1.
Animals and grouping
Male Sprague Dawley rats (8-week old, 220–240 g) were
obtained from Vital River Co. (Beijing, China; certification
Fig. 1 The structures of ten active components of Kudiezi (KDZ) injection
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number: SCXK (Jing): 2012–0001). All animals received
humane care in compliance with the Dongfang Hospital,
Beijing University of Chinese Medicine guidelines and the
research council’s criteria. Animal procedures were ap-
proved by the institutional animal care and use committee
of Dongfang Hospital, Beijing University of Chinese
Medicine. The animals were allowed to acclimatize for
5 days before experiments.
They were randomly divided into three groups: sham,
6h-ischemia, and KDZ treatment (KDZ). The rats in the
sham groups were subjected to surgical operation with-
out MCAO. In the 6h-ischemic and KDZ groups, rats
were subjected to MCAO on the left hemisphere. The
animals in the KDZ group were treated with KDZ injec-
tion (40 ml of KDZ injection mixed with 250 ml of 0.9%
sodium chloride) intraperitoneally injected at 22.65 ml/
kg within 10 min after MCAO. The sham and 6h-
ischemia groups received 0.9% sodium chloride at 1 ml/
100 g by intraperitonealinjection.
Middle cerebral artery occlusion
Rats were anesthetized with 10% chloral hydrate (3.5 ml/
kg body weight) intraperitoneally. Cerebral ischemia was
conducted according to the method by Longa et al.
[20, 21] with some modifications. A 24-mm nylon
monofilament (Cinontech Limited Company, Beijing,
China) was inserted into the internal carotid artery
through a small incision on the left common carotid
artery and advanced 18 ± 2 mm to occlude the middle
cerebral artery. The filament was left in place until
sacrifice at 6 h after occlusion (without reperfusion).
Rats in the sham group underwent the same proced-
ure without monofilament insertion.
Assessment of neurological function
Neurological deficit scoring was performed by two in-
vestigators blind to grouping at 6 h after MCAO. The
neurobehavioral scoring was performed according to the
methods of Garcia [22]: spontaneous activity (in cage
for 5 min); symmetry of movements (four limbs);
symmetry of forelimbs (outstretching while held by
tail); climbing wall of wire cage; reaction to touch on
either side of trunk; and response to vibrissae touch.
Each test is scored 0–3 points. The total scores range
3–18. The lower the score, the more severe is the
neurological impairment.
Heart rate variability (HRV)
After assessment of the neurological function, rats were
anesthetized with 10% chloral hydrate (3.5 ml/kg body
weight) intraperitoneally. The rats were implanted with
needle electrode connected with a MP100 physiography
device (Biopac Systems Inc., Goleta, CA, USA) and the
device recorded the electrocardiographic signals for
120 s, which were subsequently used to derive R-R inter-
vals. Spectral power of HRV was obtained by applying
the fast Fourier transformation (FFT) and ranged from 0
to 3 Hz. The low frequency band (LF) was integrated
over 0.04–0.20 Hz, the medium frequency band (MF)
was integrated over 0.21–0.60 Hz, and the high
frequency band (HF) was integrated over 0.61–3.0 Hz.
The MF/LF ratio was also calculated.
Blood sample and tissue collection
After the 6-h KDZ treatment, the rats were anesthetized
with 10% chloral hydrate (3.5 ml/kg body weight). Blood
was collected from the abdominal aorta. The serum was
rapidly separated from blood and processed for deter-
mination of serum creatinine kinase (CK), lactate
dehydrogenase (LDH), and creatine kinase-myocardial
band (CK-MB) activity. The brain cortex and myocardial
tissues were dissected. Changes in cortex weight were
recorded to determine brain edema.
Measurement of ischemic infarction volume and brain
water content
Coronal sections (2 mm) were immersed in 1% 2,3,5-
triphenyltetrazolium chloride (TTC) in phosphate-
buffer saline (pH 7.4) at 37 °C for 15 min and then
fixed with 10% paraformaldehyde for 10 min [5]. The
white color represented infarct tissue and the red
color represented normal tissue. TTC-stained sections
were photographed and the images were analyzed
using Image-Pro Plus 6.0 (Olympus, Tokyo, Japan) to
calculate the infarct volume. The lesion volumes were
calculated as a percentage of the contralateral hemi-
sphere volume to compensate for the effect of brain
edema using the following formula: [total infarct
volume-(volume of intact ipsilateral hemisphere-
volume of intact contralateral hemisphere)]/contralat-
eral hemisphere volume × 100% [6].
The brain water content was measured using the
standard wet dry method. A brain slice was cut and the
slice was divided into the ipsilateral and contralateral
hemispheres. The two hemisphere slices were immedi-
ately weighed to obtain the wet weight, dried for 24 h in
an oven at 100 °C, and then reweighed to obtain the dry
weight. Brain water content was calculated as a percent-
age using the following formula: [(wet weight-dry
weight)/wet weight] × 100%.
Serum CK, LDH, and CK-MB activity
Blood taken from the abdominal aorta was centrifuged
at 3500 rpm at 4 °C in a refrigerated centrifuge for
10 min. Supernatant was used for ELISA assays [Rat
LDH ELISA Kit, Enzyme-linked Biotechnology Co., Ltd.,
Shanghai, China; Rat CK ELISA Kit, Lianshuo Biological
Technology Co., Ltd., Shanghai, China; CK-MB activity
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Kit, RB, USA] and measured at 450 nm with a micro-
plate reader (RB, USA) according to the manufacture’s
protocol. The concentrations of CK-MB, CK, and LDH
was calculated and expressed as U/L.
Histological changes
Paraffin serial sections (5 μm) were prepared from cor-
tex and myocardial tissues. Sections were de-waxed and
rehydrated. Endogenous peroxidase was quenched for
20 min using 3% (v/v) hydrogen peroxide in phosphate-
buffered saline (PBS). Staining was performed using
H&E and hematoxylin basic fuchsin picric (HBFP).
Histological images were captured with a BX71 micro-
scope (Olympus, Tokyo, Japan).
Assessment of SOD activity, MDA content, and GSH content
in myocardial tissues
Myocardial tissues were rinsed, weighed, and homoge-
nized with nine volumes of 0.9% normal saline for
10 min. After centrifugation at 3000 rpm for ten minutes
at 4 °C, the supernatants were collected and used imme-
diately. The levels of MDA were determined by the TBA
method, the levels of GSH were determined by a colori-
metric method, and the activity of SOD was measured
by the hydroxylamine method, all using commercial kits
(Jiancheng Limited Company, Jiangsu, China).
Mitochondria isolation of myocardial tissue
Minced heart tissues were homogenized in MESH-BSA
(15 mL/g tissue). The homogenates were centrifuged at
1500 g for 5 min to remove cell debris and the nuclear
fraction. The supernatant was further centrifuged at
13,000 × g for 10 min. The pellet was resuspended in
20 mL of MESH buffer and centrifuged at 13,000 × g for
10 min. The mitochondria pellet was suspended in
0.5 mL of MESH per g of tissue to yield a protein con-
centration of 25 mg/mL, according to the manufacturer’s
instructions (Tissue mitochondria isolation kit, Biosea
Biotechnology Limited Company, Beijing, China).
Measurement of COX activity in myocardial mitochondria
COX activity in mitochondria of myocardial tissues was
measured at 550 nm using the reduced cytochrome c
method, according to the manufacturer’s instructions
(COX activity kit, Jiemei Gene Limited Company,
Shanghai, China).
Semi-quantitative RT-PCR analysis
Total mitochondrial RNA was isolated from myocardial
tissues using Trizol (Invitrogen Inc., Carlsbad, CA,
USA), and then reverse-transcribed using the RT-PCR
ReverTra-PlusTM kit (TOYOBO Co., Ltd, Tokyo, Japan)
according to the manufacturer’s instructions. Semi-
quantitative RT-PCR analysis of COX I and COX III
mRNA expressions was performed using the Prime Script
RT-PCR kit (Clontech Laboratories Inc., Mountain View,
CA, USA) according to the manufacturer’s instructions and
a PCR system (AG-22331; Eppendorf, Hamburg, Germany).
Glyceraldehyde-3-phosphatedehydrogenase (GAPDH) was
used as control. The primers were: COX I: forward: 5′-
GGC TTC GGG AAC TGA CTT GT-3′, reverse: 5′-AAG
GAT TGG GTC TCC ACC TC-3′ (annealing temperature:
60 °C; 30 cycles; PCR product: 462 bp); COX III: forward:
5′-GCC ACC ACA CCC CTA TTG TA-3′, reverse: 5′-
TCC CGT TGC TAT GAA GAA TG-3′ (annealing
temperature: 60 °C; 30 cycles; PCR product: 401 bp), and
GAPDH: forward: 5′-TGT TCC TAC CCC CAATGT GT-
3′, reverse: 5′-CCC TGT TGC TGTAGC CGTAT-3′ (an-
nealing temperature: 60 °C; 30 cycles; PCR product:
401 bp). The relative expression of mRNA of a specific gene
to the internal control was calculated as the ratio of relative
optical density using a gel imaging analyzer (EPS301; GE
Healthcare, Waukesha, WI, USA) with gel analysis software
(GE Healthcare, Waukesha, WI, USA).
Statistical analysis
All data were expressed as mean ± standard error of the
mean (SEM) and analyzed using the independent sample
t test (for infarct volume and brain edema) or one-way
analysis of variance (ANOVA) with the least significant
difference (LSD) as post hoc test (for all other analyses),
as appropriate. All analyses were performed with SPSS
17.0 (IBM, Armonk, NY, USA). Two-sided P-values
< 0.05 were considered statistically significant.
Fig. 2 Effects of KDZ injection on the neurological function of rat models
of focal cerebral ischemia Sham: rats were subjected to surgical operation
without occlusion of the right middle cerebral artery (MCAO) and without
KDZ treatment; 6h-ischemia: rats were subjected to MCAO without KDZ
treatment; and KDZ: rats were subjected to MCAO and KDZ treatment.
Neurological impairment was evaluated using the Garcia score.
Data are shown as mean ± standard error of the mean (SEM)
(n = 8/group). **P < 0.01 vs. sham; ##P < 0.01 vs. 6h-ischemia
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Results
KDZ injection improved neurological function in a focal
cerebral ischemia rat model
The rats in sham group could walk in a straight line and
had a steady gait, both forelimbs could unbend, and
there was no neurological damage. Garcia scores were
about 18. The rats in the 6h-ischemia group walked
slowly and failed to flex their left forelimb fully. The rats
could not walk straightly and leaned to the left. The
Garcia scores in the 6h-ischemia group were lower than
sham group (7.50 ± 1.41, P < 0.01). Moreover, the Garcia
cores in the KDZ group were significantly higher than
those in the 6h-ischemia group despite that it was
still lower than in the sham group (10.25 + 1.28, both
P < 0.01) (Fig. 2).
KDZ injection reduced cerebral infarct volume and brain
water content in the focal cerebral ischemia rat model
Brain infarct volume was measured with TTC staining.
Rats in the sham group had no ischemic damage. Rats in
the 6h-ischemia group had an infarct volume of 31.01 ±
1.43%, whereas KDZ treatment decreased the volume to
14.57 ± 2.41% (P < 0.01; Fig. 3a). In the 6h-ischemia
group, cerebral brain water content was 83.83 ± 1.06%,
whereas in the KDZ group, it was lowered to 80.06 ±
0.38% (P < 0.01; Fig. 3b).
Fig. 3 Effects of KDZ injection on the infarct volume and brain edema of
rat models of focal cerebral ischemia. a Infarct volume was determined by
2,3,5-triphenyltetrazolium chloride staining shown as white color. Infarct
volume (%) in the 6h-ischemia and KDZ groups was quantitatively
evaluated. b Brain edema (%) in the 6h-ischemia and KDZ groups. Data
are shown as mean± SEM (n= 8/group). ##P< 0.01 vs. 6h-ischemia
Fig. 4 Effects of KDZ injection on serum creatinine kinase (CK), lactate
dehydrogenase (LDH), and creatine kinase-myocardial band (CK-MB)
activity of rat models of focal cerebral ischemia. a CK-MB activity, b CK,
and c LDH were determined by ELISA. Data are shown as mean ± SEM
(n = 10/group for CK-MB activity; n = 12/group for CK and LDH).
*P < 0.05, **P < 0.01 vs. sham; #P < 0.05, ##P < 0.01 vs. 6h-ischemia
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KDZ injection decreased CK-MB activity, and CK and LDH
levels in serumin the focal cerebral ischemia rat model
We measured the CK, LDH, and CK-MB activity in the
serum of the rats as indications of myocardial damage or
infarction. CK-MB activity was 5.01 ± 0.29 U/L in the
sham group, and was increased to 11.01 ± 1.14 U/L at 6 h
post-ischemia (P < 0.01 vs. the sham group), whereas it
was declined to 5.87 ± 0.54 U/L in the KDZ group
(P < 0.01 vs. the 6h-ischemia group) (Fig. 4a). LDH
levels were 160.0 ± 13.7 U/L in the sham group, and was
increased to 404.8 ± 26.1 U/L at 6 h post-ischemia
(P < 0.01 vs. the sham group), whereas it was declined to
269.4 ± 23.4 U/L in the KDZ group (P < 0.01 vs. the 6h-
ischemia group) (Fig. 4b). CK levels were 409.8 ± 46.0 U/L
in the sham group, and was increased to 1019.5 ± 165.8
U/L at 6 h post-ischemia (P < 0.01 vs. the sham group),
whereas it was declined to 633.0 ± 101.7 U/L in the KDZ
group (P < 0.05 vs. the 6h-ischemia group) (Fig. 4c).
KDZ injection alleviated the myocardial ischemic changes
in the focal cerebral ischemia rat model
Myocardial ischemic changes (widened myocardial cell gap,
cracks, and obvious edema) were detected by H&E staining
6h after MCAO (Fig. 5). These lesions were alleviated in
the KDZ group, as shown by lower edema of myocardial
cells and smaller gaps (Fig. 5). HBFP staining is a non-
enzymatic histochemical technique to detect early myocar-
dial ischemia [23]. Myocardial ischemia was observed in
the endocardial myocardium and musculi papillary, and the
middle of the ventricular wall at 6h after cerebral ischemia.
Myocardial ischemia was alleviated in the KDZ group com-
pared with the 6h-ischemia group (Fig. 5).
KDZ injection increased MF and HF in the focal cerebral
ischemia rat model
HRV is of substantial importance to evaluate autonomic
control mechanisms and to identify patients with an
Fig. 5 Effects of KDZ injection on changes of myocardial histomorphology of rats models of acute cerebral ischemia by H&E staining and
hematoxylin-basic fuchsin picric (HBFP) staining (magnification: ×200). In the sham group, H&E staining showed that cardiomyocyte morphology was
normal, myofibrils were orderly arranged, and myocardial cell gaps were uniform. In the 6h-ischemia group, myofibril arrangement was disorderly,
myocardial cell gaps were widened, cracks had appeared, and edema was obvious. In the KDZ group, myocardial cell edema was decreased and gaps
were smaller. Arrows: gaps. In the sham group, HBFP staining showed that myocardial fibers were golden and the nuclei were blue. In the 6h-ischemia
group, myocardial fibers were red and arranged in large sheets with diffuse distribution and dark red staining. In the KDZ group, compared with the
model group, red staining of myocardium fiberswas weaker, with a smaller number, and more dispersed
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increased risk of myocardial mortality [24]. HRV is
mainly composed of LF, MF, and HF. MF is affected by
both sympathetic and parasympathetic myocardial activ-
ities. HF is a quantitative indicator for the detection of
myocardial parasympathetic activity. The MF/HF ratio
reflects the balance of sympathetic and parasympathetic
myocardial activity. In the 6h-ischemia group, MF and
HF were lower compared with the sham group (both
P < 0.05). After KDZ treatment, MF and HF were higher
than in the 6h-ischemia group (both P < 0.05) (Table 1).
KDZ injection increased SOD activity and GSH content
and decreased MDA content in myocardial tissue after
brain ischemia
There was no difference in the levels of SOD activity,
GSH, and MDA contents in myocardial tissues in the
6h-ischemia group compared with the sham group (all
P > 0.05). Compared with the 6h-ischemia group, SOD
activity and GSH content were significantly increased
(both P < 0.05) while the MDA levels were reduced in
the KDZ group (P < 0.05) (Fig. 6).
KDZ injection has no effect on COX activity in the
mitochondria of myocardial tissues after brain ischemia
Compared with the sham group, COX activities were
higher in the mitochondria of myocardial tissues of
the 6h-ischemia and KDZ groups (both P < 0.01).
Compared with the 6h-ischemia group, there was no
significant change in COX activity in the KDZ group
(P > 0.05) (Fig. 7).
KDZ injection enhanced the expressions of COXI and
COXIII mRNA in the mitochondria of myocardial tissues
after brain ischemia
RT-PCR results showed that the expressions of COX I
and COX III mRNA were not different between the 6h-
ischemia and sham groups (both P > 0.05). Compared
with the 6h-ischemia and sham groups, COX I (both
P < 0.01) and COX III mRNA (both P < 0.05) were
significantly higher in the KDZ group (Fig. 8).
Discussion
Heart failure and ischemic brain stroke are major causes of
mortality and disability around the world [25]. Sometimes,
the failure of these two organs occurs simultaneously,
Table 1 Effect of Kudiezi injection on heart rate variability in rat models of focal cerebral ischemia
Group LF (S2/Hz) MF (S2/Hz) HF (S2/Hz) MF/HF
Sham 0.0183 ± 0.0032 0.070 ± 0.0124 0.0230 ± 0.0041 3.017 ± 0.004
6h-ischemia 0.0166 ± 0.0035 0.059 ± 0.0125* 0.0194 ± 0.0036* 3.023 ± 0.006
KDZ 0.0162 ± 0.040 0.064 ± 0.0128# 0.0212 ± 0.0040# 3.018 ± 0.007
Data are shown as mean ± standard error of the mean (SEM) (n = 12/group)
LF low frequency band, MF middle frequency band, HF high frequency band, KDZ Kudiezi injection
*P < 0.05 vs. sham group; #P < 0.05 vs. the 6h-ischemic group
Fig. 6 Effects of KDZ injection on SOD activity and MDA and GSH
content in myocardial tissues of rat models of focal cerebral ischemia.
Data are shown as mean ± SEM (n = 12/group). *P < 0.05 vs. sham; #P
< 0.05 vs. 6h-ischemia
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resulting in a more severe condition [6]. The present study
focused on myocardial injury following ischemic stroke
using rodent experimental stroke models. Myocardial injury
due to brain damage has been previously reported [4, 26].
Although clinical studies have convincingly demonstrated
that myocardial injury occurs after cerebral ischemia [4, 26],
results from animal studies are still inconsistent, especially
at the early stage of acute ischemic stroke [27–29]. The
present study strongly suggests that cerebral ischemia could
indeed lead to myocardial injury.
Results showed that a 6-h occlusion of the middle
cerebral artery of rats resulted in brain functional defi-
cits and edema, with concomitant morphological and
biochemical changes in the heart. The myocardial tissue
showed histopathological changes that are characteristics
of myocardial damage, as supported by higher CK-MB
activity and CK and LDH levels in the serum of the rats
of the 6h-ischemia group [30, 31]. MF and HF were
depressed in ECG recording, but the MF/TF ratio
remained unchanged after brain ischemia, suggesting
that the balance of the autonomic nervous system was
not altered. Increased mitochondrial cytochrome c activ-
ity in myocardial tissue might precede the release of
cytochrome c into the cytosol and activation of the
apoptosis pathways. These findings suggest that acute
cerebral ischemia could be a causative event leading to
myocardial injury [4, 26].
We further investigated whether KDZ injection is
protective against ischemic brain and myocardial in-
jury, and we explored the underlying mechanisms.
We found that, in addition to its protection against
brain injury, KDZ injection could also alleviate myo-
cardial injury after acute cerebral ischemia. Possibly
involved mechanisms include the regulation of oxi-
dative stress and mitochondrial enzyme activity.
Measuring by products of lipid peroxidation such as
MDA is one of the most widely accepted assays for
oxidative stress. In the present study, MDA levels in
myocardial tissues were decreased with KDZ injec-
tion suggesting alleviated oxidative stress. Mean-
while, KDZ could enhance anti-oxidative defense of
myocardial tissues, as evidenced by the increased
levels of GSH and SOD activity.
COX is a crucial component of the mitochondrial re-
spiratory chain and is of outmost importance for provid-
ing cellular energy [11]. The contribution of COX to
ROS production and oxidative stress remains controver-
sial. While increased COX activity has been associated
with increased oxidative stress [10, 12], COX inhibition
was also found to result in increased susceptibility to
oxidative stress and to accelerate mitochondrial apop-
tosis in response to oxidative stress [13]. KDZ injection
was shown to increase COX I and COX III mRNA
expression, but the overall mitochondrial COX activity
was similar to that of injured animals without KDZ
treatment. Whether these changes are relevant to the
protective effects of KDZ needs further investigation.
In the present study, to evaluate myocardial function
after focal brain ischemia, HRV, which refers to the sinus
rhythm within a certain time, was recorded. HRV can be
used to quantitatively assess the effects of stroke on the
myocardial sympathetic nerve, vagua nerve, and their
balance [24]. HRV is a good indicator of the function of
Fig. 7 Effect of KDZ injection on mitochondrial COX activity in myocardial
tissues of rat models of focal cerebral ischemia. Mitochondrial COX activity
was measured at 550 nm by the reduced cytochrome c method. Data are
shown as mean± SEM (n= 6/group). **P<0.01 vs. sham
Fig. 8 Effects of KDZ injection on the expressions of mitochondrial COX I and COX III mRNA in myocardial tissues of rat models of focal cerebral
ischemia. Expressions of mitochondrial COX I and COX III mRNA were determined by RT-PCR. GAPDH was used as control. Data are shown as
mean ± SEM (n = 6/group). *P < 0.05, **P < 0.01 vs. sham; #P < 0.05, ##P < 0.01 vs. 6h-ischemia
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the autonomic nervous system of the heart sinus. A re-
duction in HRV is an independent predictor of cardiac
arrhythmias and sudden cardiac death [24, 32]. We
showed that MF, HF, and total TF were significantly
reduced in the 6h-ischemia group, which could be re-
stored by KDZ injection. The data suggested that the
total autonomic activity was significantly impaired by
6-h ischemia and that the function of sympathetic and
parasympathetic nerves might be affected after acute
cerebral ischemia, which might be associated with sec-
ondary heart injury. This finding is in agreement with
previous clinical and experimental studies showing re-
duced MF and HF, and increased MF/HF ratio in pa-
tients with cerebral artery occlusion (including insular
infarction) [33, 34]. KDZ has the benefits of correcting
the myocardial dysfunction after brain ischemia.
Skeletal muscles express 1% of CK-MB and 98%
CK-MM, while the cardiac muscle expresses 25–30%
CK-MB and 70% CK-MM [35]. Therefore, CK-MB is an
appropriate marker of cardiac injury. In the present
study, KDZ reversed, in part, the increases in CK-MB,
CK, and LDH levels that occurred after acute ischemic
stroke. Furthermore, cardiac injury caused by acute is-
chemic stroke could be attributed, at least in part, to
oxidative stress. Similar increases in CK-MB, CK, and
LDH levels have been attributed to oxidative stress by a
number of studies [30, 31, 36]. A previous study showed
that vitamin C (an antioxidant) decreased CK-MB, CK,
and LDH levels in mice models of cardiotoxicity, support-
ing the oxidative stress hypothesis of cardiotoxicity [30].
Conclusions
The present study suggests that KDZ injection could have
a protective effect against cerebral ischemia in rats. It
could also alleviate myocardial injury secondary to acute
cerebral ischemia in rats. The possible mechanisms in-
volved the regulation of oxidative stress in myocardial
tissue after cerebral ischemia in rats. Pharmacological
intervention in these aspects may represent a targeted and
mechanism-based therapeutic strategy against myocardial
injury following cerebral ischemia.
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